Lexatumumab ELISA Kit|Lexatumumab ELISA试剂盒(靶标：)
- 货号：RB9TDT348048
- 价格：面议
- 点击：374
产品介绍
产品参数
| 应用 | ELISA |
|---|---|
| 检测方法 | Colorimetric |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 样本类型 | Plasma, Serum |
| 检测类型 | Quantitative |
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 运输条件 | 2-8 ℃ |
| 登录号 | O14763 |
| 背景信息 | Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL). It was developed by Genentech as a drug for the treatment of cancers. This drug has been investigating in various trials for treating cancers including chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. The efficacy and selectivity of drozitumab in rhabdomyosarcoma (RMS) has been evaluated in preclinical models. And results showed that drozitumab is effective, in vitro, against the majority of RMS cell lines that express caspase-8 and, in vivo, may provide long-term control of RMS. In preclinical glioblastoma models, drozitumab has been found to induce apoptosis and colony formation in several glioblastoma cell lines combined with BV6 (combination index<0.1). A study about triple-negative breast cancer reported that drozitumab could induce apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes. The previous study about the treatment of pancreatic ductal adenocarcinoma has revealed that drozitumab could selectively eliminate CSCs, resulting in tumor growth inhibition and even regression of pancreatic tumors. |
| 别名 | HGS-ETR2, 845816-02-6 |
| 备注 | For Research Use Only. |
相关产品: